Switch theme
Sign up to access all valuation multiples
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
2018
20
LTM Revenue $6.9M
Last FY EBITDA -$35.7M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Belite Bio has a last 12-month revenue (LTM) of $6.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Belite Bio achieved revenue of n/a and an EBITDA of -$35.7M.
Belite Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Belite Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $6.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$35.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$41.9M | XXX | -$40.0M | XXX | XXX | XXX |
| EBIT Margin | -607% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$38.9M | XXX | -$36.1M | XXX | XXX | XXX |
| Net Margin | -564% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Belite Bio's stock price is $65.
Belite Bio has current market cap of $2.1B, and EV of $2.0B.
See Belite Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.1B | XXX | XXX | XXX | XXX | $-1.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Belite Bio has market cap of $2.1B and EV of $2.0B.
Belite Bio's trades at n/a EV/Revenue multiple, and -55.3x EV/EBITDA.
Equity research analysts estimate Belite Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Belite Bio has a P/E ratio of -54.4x.
See valuation multiples for Belite Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 286.1x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -55.3x | XXX | XXX | XXX |
| EV/EBIT | -47.1x | XXX | -49.3x | XXX | XXX | XXX |
| EV/Gross Profit | 286.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -54.4x | XXX | -58.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -67.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBelite Bio's last 12 month revenue growth is 92%
Belite Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Belite Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Belite Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Belite Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 92% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Belite Bio acquired XXX companies to date.
Last acquisition by Belite Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Belite Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Belite Bio founded? | Belite Bio was founded in 2018. |
| Where is Belite Bio headquartered? | Belite Bio is headquartered in United States of America. |
| How many employees does Belite Bio have? | As of today, Belite Bio has 20 employees. |
| Who is the CEO of Belite Bio? | Belite Bio's CEO is Dr. Yu-Hsin Lin. |
| Is Belite Bio publicy listed? | Yes, Belite Bio is a public company listed on NAS. |
| What is the stock symbol of Belite Bio? | Belite Bio trades under BLTE ticker. |
| When did Belite Bio go public? | Belite Bio went public in 2022. |
| Who are competitors of Belite Bio? | Similar companies to Belite Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Belite Bio? | Belite Bio's current market cap is $2.1B |
| What is the current revenue of Belite Bio? | Belite Bio's last 12 months revenue is $6.9M. |
| What is the current revenue growth of Belite Bio? | Belite Bio revenue growth (NTM/LTM) is 92%. |
| What is the current EV/Revenue multiple of Belite Bio? | Current revenue multiple of Belite Bio is 286.1x. |
| Is Belite Bio profitable? | Yes, Belite Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
